The details of a groundbreaking cancer study were announced Monday in Chicago, where researchers are meeting for the conference of the American Society of Clinical Oncology. Most cancer treatment revolves around the type of cancer a patient has. But in a new trial starting in July, the focus will be on the genes. Patients will have their tumor genes sequenced in order to determine which drugs will be administered. Dr. Jeff Abrams, Acting Director for Clinical Research and Associate Director of the Cancer Therapy Evaluation Program in the National Cancer Institute’s Division of Cancer Treatment and Diagnosis, joins with details on the new trial.